ReviewMolecules (Basel, Switzerland)2022
Griseofulvin: An Updated Overview of Old and Current Knowledge.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses.Clinical pharmacokinetics · 2025Pooled it
- Identification of new ER-targeted anticancer hits active against MCF-7 breast cancer cells in the marine fungal secondary metabolite library using computative and experimental approaches.Journal of computer-aided molecular design · 2026Article
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Discovery of Forvisirvat (DS-7830a/SP-624), a Brain-Penetrant Sirtuin 6 Activator Derived from Griseofulvin with Antidepressant-Like Effects.ACS medicinal chemistry letters · 2026Article
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparative Efficacy of Terbinafine, Itraconazole, and Griseofulvin in Treatment of Steroid-Modified Tinea.Indian dermatology online journal · 2026Article
- Occurrence and Co-Occurrence of Regulated and Emerging Mycotoxins in Foods Marketed to U.S. Toddlers.International journal of environmental research and public health · 2026Article
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Mining the Hidden Pharmacopeia: Fungal Endophytes, Natural Products, and the Rise of AI-Driven Drug Discovery.International journal of molecular sciences · 2026Review
- Antifungal Biocontrol in Sustainable Crop Protection: Microbial Lipopeptides, Polyketides, and Plant-Derived Agents.Journal of fungi (Basel, Switzerland) · 2025Review
- Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds.International journal of molecular sciences · 2025Review
- Article
- Pathogenesis and treatment strategies for infectious keratitis: Exploring antibiotics, antimicrobial peptides, nanotechnology, and emerging therapies.Journal of pharmaceutical analysis · 2025Review
- Article
- Thiazole Derivatives as Promising Candidates for Cryptococcosis Therapy.ACS infectious diseases · 2025Article
- Fungal Metabolomics: A Comprehensive Approach to Understanding Pathogenesis in Humans and Identifying Potential Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Review
- Nutritional valorization of Manila tamarind accessions through antioxidant analysis and UHPLC-Q-TOF-MS-based metabolomic profiling.Frontiers in nutrition · 2025Article
- Enhancing Antifungal Drug Discovery Through Co-Culture with AntarcticInternational journal of molecular sciences · 2024Article
- Ionic resorcinarenes as drug solubilization agents in water.RSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Griseofulvin is an antifungal polyketide metabolite produced mainly by ascomycetes. Since it was commercially introduced in 1959, griseofulvin has been used in treating dermatophyte infections. This fungistatic has gained increasing interest for multifunctional applications in the last decades due to its potential to disrupt mitosis and cell division in human cancer cells and arrest hepatitis C virus replication. In addition to these inhibitory effects, we and others found griseofulvin may enhance ACE2 function, contribute to vascular vasodilation, and improve capillary blood flow. Furthermore, molecular docking analysis revealed that griseofulvin and its derivatives have good binding potential with SARS-CoV-2 main protease, RNA-dependent RNA polymerase (RdRp), and spike protein receptor-binding domain (RBD), suggesting its inhibitory effects on SARS-CoV-2 entry and viral replication. These findings imply the repurposing potentials of the FDA-approved drug griseofulvin in designing and developing novel therapeutic interventions. In this review, we have summarized the available information from its discovery to recent progress in this growing field. Additionally, explored is the possible mechanism leading to rare hepatitis induced by griseofulvin. We found that griseofulvin and its metabolites, including 6-desmethylgriseofulvin (6-DMG) and 4- desmethylgriseofulvin (4-DMG), have favorable interactions with cytokeratin intermediate filament proteins (K8 and K18), ranging from -3.34 to -5.61 kcal mol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.